The partners plan to build evidence packages that standardize comprehensive genomic profiling and other molecular testing ...

Tempus AI has launched an advisory board of oncology experts to provide guidance and strategic advice to the Chicago-based company on research, product development and clinical use of it's AI-enabled ...

Artificial intelligence (AI) is rapidly being integrated into every domain of healthcare, giving birth to a new class of tech ...

"In that vein, we have formed the Tempus Advisory Board which solidifies this intent and overall mission. We are thrilled to gather this group of internationally renowned, experienced, and passionate ...

Illumina is teaming up with Tempus AI for a project aimed at promoting the use of DNA sequencing tests across all major areas ...

BofA lowered the firm’s price target on Tempus AI (TEM) to $48 from $60 and keeps a Neutral rating on the shares. Sentiment for Life Sciences ...

Illumina (ILMN) and Tempus AI (TEM) announced a collaboration to accelerate clinical adoption of next-generation sequencing tests through novel ...

Illumina Inc. (NASDAQ: ILMN) and Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced a collaboration to ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Artificial intelligence (AI) is rapidly being integrated into every domain of healthcare, giving birth to a new class of tech-driven innovators. Tempus AI TEM and Doximity DOCS stand out as ...